May 4, 2026 06:37AM Cabaletta Bio prices $150 million stock offering at $2.90 per share

Apr 29, 2026 07:25AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Apr 1, 2026 06:58AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Mar 27, 2026 10:55AM Jefferies on Cabaletta Bio Inc. (CABA): 'we see solid setup from here'

Mar 23, 2026 09:08PM Cabaletta Bio, Inc. (CABA) Tops Q4 EPS by 6c

Mar 23, 2026 04:57PM Jefferies on Cabaletta Bio Inc. (CABA): liking setup as co 'is heading into an inflection point'

Mar 23, 2026 04:44PM William Blair maintains Outperform rated on Cabaletta Bio Inc. (CABA) amid trial progress

Mar 23, 2026 01:54PM Cabaletta Bio Inc. (CABA) PT Raised to $16 at Guggenheim

Mar 23, 2026 01:53PM Cabaletta Bio Inc. (CABA) PT Raised to $16 at Guggenheim

Jan 27, 2026 07:09AM Guggenheim Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Jan 16, 2026 07:10AM Cabaletta Bio (CABA) Reiterated at Overweight by Cantor Fitzgerald

Jan 12, 2026 08:10AM Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy

Jan 12, 2026 07:31AM FDA clears Cabaletta Bio's rese-cel for automated manufacturing platform

Nov 10, 2025 07:42AM Cabaletta Bio, Inc. (CABA) Tops Q3 EPS by 3c

Oct 28, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Oct 10, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)

Oct 10, 2025 06:37AM Increasing unusual call option volume: CABA LNC TD RVPH GDRX GGAL TE CODI WWR

Oct 10, 2025 05:30AM Jefferies Resumes Cabaletta Bio Inc. (CABA) at Buy

Sep 24, 2025 06:46AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)

Aug 14, 2025 04:29PM Cabaletta Bio Inc. (CABA) PT Lowered to $10 at Citi

Aug 8, 2025 08:33AM Cabaletta Bio Inc. (CABA) PT Lowered to $15 at Guggenheim

Aug 7, 2025 04:52PM Cabaletta Bio Inc. (CABA) PT Lowered to $14 at Jefferies

Jun 27, 2025 11:31AM FDA removing REMS from several CAR-T cell therapies positive for these 3 stocks - William Blair

Jun 13, 2025 07:03AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)

Jun 12, 2025 08:13AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Jun 11, 2025 09:56AM Cabaletta Bio (CABA) Prices Share Offering at $2/sh

Jun 11, 2025 06:15AM Cabaletta Bio (CABA) Announces Proposed Share Offering

Jun 11, 2025 06:01AM Cabaletta Bio (CABA) Announces New Rese-cel Safety and Efficacy Data

Apr 1, 2025 09:04AM Cabaletta Bio Inc. (CABA) PT Lowered to $7 at UBS

Mar 31, 2025 01:11PM Cabaletta Bio Inc. (CABA) PT Lowered to $13 at Stifel

Feb 18, 2025 07:03AM Cabaletta Bio (CABA) Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Jan 17, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Nov 19, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Nov 18, 2024 07:00AM Cabaletta Bio (CABA) Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Nov 14, 2024 01:47PM Guggenheim Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Oct 10, 2024 03:51AM UBS Starts Cabaletta Bio Inc. (CABA) at Buy

Sep 17, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Aug 16, 2024 05:31AM Stifel Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)

Aug 8, 2024 09:25AM Cabaletta Bio, Inc. (CABA) Misses Q2 EPS by 1c

Jun 17, 2024 05:29AM Citi Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)